Literature DB >> 21742969

NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Stephen R Mattarollo1, Michelle Yong, Christina Gosmann, Allison Choyce, Dora Chan, Graham R Leggatt, Ian H Frazer.   

Abstract

We recently demonstrated that CD1d-restricted NKT cells resident in skin can inhibit CD8 T cell-mediated graft rejection of human papillomavirus E7-expressing skin through an IFN-γ-dependent mechanism. In this study, we examined the role of systemically derived NKT cells in regulating the rejection of skin grafts expressing viral proteins. In lymph nodes draining transplanted skin, Ag-specific CD8 T cell proliferation, cytokine production, and cytotoxic activity were impaired by NKT cells. NKT cell suppression was mediated via CD11c(+) dendritic cells. Inhibition of CD8 T cell function did not require Foxp3(+) regulatory T cells or NKT cell-secreted IFN-γ, IL-10, or IL-17. Thus, following skin grafting or immunization with human papillomavirus-E7 oncoprotein, NKT cells reduce the capacity of draining lymph node-resident APCs to cross-present Ag to CD8 T cell precursors, as evidenced by impaired expansion and differentiation to Ag-specific CD8 T effector cells. Therefore, in the context of viral Ag challenge in the skin, systemic NKT cells limit the capacity for effective priming of adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742969      PMCID: PMC3150369          DOI: 10.4049/jimmunol.1100756

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.

Authors:  Ian F Hermans; Jonathan D Silk; Uzi Gileadi; Mariolina Salio; Bini Mathew; Gerd Ritter; Richard Schmidt; Adrian L Harris; Lloyd Old; Vincenzo Cerundolo
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes.

Authors:  Yi-Guang Chen; Caroline-Morgane Choisy-Rossi; Thomas M Holl; Harold D Chapman; Gurdyal S Besra; Steven A Porcelli; Daniel J Shaffer; Derry Roopenian; S Brian Wilson; David V Serreze
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity.

Authors:  Keunhee Oh; Sanghee Kim; Se-Ho Park; Hua Gu; Derry Roopenian; Doo Hyun Chung; Yon Su Kim; Dong-Sup Lee
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

4.  Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts.

Authors:  Jan Novak; Lucie Beaudoin; Thibault Griseri; Agnès Lehuen
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

5.  Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity.

Authors:  Sharmal Narayan; Allison Choyce; Germain J P Fernando; Graham R Leggatt
Journal:  Eur J Immunol       Date:  2007-02       Impact factor: 5.532

6.  Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal.

Authors:  L A Dunn; M Evander; R W Tindle; A L Bulloch; R L de Kluyver; G J Fernando; P F Lambert; I H Frazer
Journal:  Virology       Date:  1997-08-18       Impact factor: 3.616

7.  Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.

Authors:  Koji Matsumoto; Graham R Leggatt; Jie Zhong; Xiaosong Liu; Rachel L de Kluyver; Tania Peters; Germain J P Fernando; Amy Liem; Paul F Lambert; Ian H Frazer
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

8.  Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells.

Authors:  Sharmal Narayan; Allison Choyce; Richard Linedale; Nicholas A Saunders; Alison Dahler; Emily Chan; Germain J Fernando; Ian H Frazer; Graham R Leggatt
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  19 in total

1.  IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Authors:  Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

Review 2.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

3.  Monoclonal Invariant NKT (iNKT) Cell Mice Reveal a Role for Both Tissue of Origin and the TCR in Development of iNKT Functional Subsets.

Authors:  Eleanor Clancy-Thompson; Gui Zhen Chen; Paul M Tyler; Mariah M Servos; Marta Barisa; Patrick J Brennan; Hidde L Ploegh; Stephanie K Dougan
Journal:  J Immunol       Date:  2017-06-02       Impact factor: 5.422

4.  Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Sachi R Chaudhari; Jing Han; Chelsea M Peterson; Robert T Warren; Madison M Hart; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.426

5.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

6.  Rescue of virulent class I Newcastle disease virus variant 9a5b-D5C1.

Authors:  Yang Yu; Xusheng Qiu; Dan Xu; Yuan Zhan; Chunchun Meng; Nana Wei; Hongjun Chen; Lei Tan; Shengqing Yu; Xiufan Liu; Aijian Qin; Chan Ding
Journal:  Virol J       Date:  2012-06-18       Impact factor: 4.099

7.  Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7.

Authors:  Deepak Mittal; Andrew J Kassianos; Lee S Tran; Anne-Sophie Bergot; Christine Gosmann; Janin Hofmann; Antje Blumenthal; Graham R Leggatt; Ian H Frazer
Journal:  J Invest Dermatol       Date:  2013-05-07       Impact factor: 8.551

8.  Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes.

Authors:  Allison Choyce; Michelle Yong; Sharmal Narayan; Stephen R Mattarollo; Amy Liem; Paul F Lambert; Ian H Frazer; Graham R Leggatt
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

Review 9.  Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response.

Authors:  Alfredo Amador-Molina; José Fernando Hernández-Valencia; Edmundo Lamoyi; Adriana Contreras-Paredes; Marcela Lizano
Journal:  Viruses       Date:  2013-10-28       Impact factor: 5.048

10.  The function of the chemokine receptor CXCR6 in the T cell response of mice against Listeria monocytogenes.

Authors:  Kira Heesch; Friederike Raczkowski; Valéa Schumacher; Stefanie Hünemörder; Ulf Panzer; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.